

Lumea Selects Tempus to Advance AI-Driven Digital Pathology Solutions

Lumea, a leader in digital pathology solutions, has chosen Tempus, a leader in artificial intelligence and precision medicine, to create AI-enabled solutions

LEHI, UTAH, UNITED STATES, August 4, 2022 /EINPresswire.com/ -- [Lumea](#) Inc, a leader in integrated digital pathology solutions, has chosen [Tempus](#), a leader in artificial intelligence and precision medicine, to create AI-enabled

solutions that aim to significantly improve the level of care for cancer patients.



Tempus is developing algorithms to detect potential, actionable genetic alterations using whole-slide pathology images on Lumea's digital pathology platform, BxLink®. This technology has the potential to screen cancer patients for clinically actionable biomarkers to identify those within the Lumea system who would benefit from molecular profiling and may qualify for targeted therapies.

"The challenge today is that it is not feasible to screen every cancer patient for specific genetic mutations," stated John Wirthlin, CEO of Lumea. "Tempus' AI technology can digitally screen all patients on Lumea's platform for potential actionable genetic alterations and then identify patients who may benefit from subsequent molecular profiling. This knowledge gives those patients and their physicians the information they need to choose the best treatment options, which will significantly improve patient care."

Tempus will present details of their latest AI-driven, digital pathology work, directly accessible within Lumea's BxLink software as a result of this collaboration, at Lumea's first-of-its-kind [Digital Diagnostic Summit](#) this fall in Park City, Utah. There are limited spots available, so register now to learn more exciting digital pathology trends from Tempus, Lumea, and other leaders in the field. You will also have the opportunity to connect with colleagues at the vanguard of high-volume digital pathology implementation.

About Lumea

Lumea is the market leader in the field of integrated digital pathology solutions. Its proprietary platform leverages new technologies to drive significant improvements in biopsy handling, tracking, workflow, and diagnosis. Lumea's technology results in measurably better quality, efficiency, and cost savings throughout the diagnostic process. To learn more about the benefits of using Lumea's technology, please visit lumea.net

About Tempus

Tempus is a technology company advancing precision medicine through the practical application of artificial intelligence in healthcare. With one of the world's largest libraries of clinical and molecular data, and an operating system to make that data accessible and useful, Tempus enables physicians to make near real-time, data-driven decisions to deliver personalized patient care and in parallel facilitates discovery, development and delivery of optimal therapeutics. The goal is for each patient to benefit from the treatment of others who came before by providing physicians with tools that learn as the company gathers more data. For more information, visit tempus.com.

Bianca Collings

Lumea

[email us here](#)

This press release can be viewed online at: <https://www.einpresswire.com/article/584334950>

EIN Presswire's priority is source transparency. We do not allow opaque clients, and our editors try to be careful about weeding out false and misleading content. As a user, if you see something we have missed, please do bring it to our attention. Your help is welcome. EIN Presswire, Everyone's Internet News Presswire™, tries to define some of the boundaries that are reasonable in today's world. Please see our Editorial Guidelines for more information.

© 1995-2022 Newsmatics Inc. All Right Reserved.